TRIAVIL 4-10
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIAVIL 4-10 (TRIAVIL 4-10).
TRIAVIL 4-10 contains perphenazine, a typical antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the limbic system, basal ganglia, and hypothalamus, and amitriptyline, a tricyclic antidepressant that inhibits serotonin and norepinephrine reuptake.
| Metabolism | Perphenazine: extensively metabolized by CYP2D6, CYP3A4, and CYP1A2. Amitriptyline: metabolized by CYP2C19 and CYP2D6 to nortriptyline (active). |
| Excretion | Primarily renal (about 50-70% as metabolites, <5% unchanged) and fecal (30-50% via biliary elimination). |
| Half-life | Amitriptyline: 10-28 hours (mean 21 hours); perphenazine: 8-12 hours (mean 10 hours). Clinically, steady-state achieved in 3-5 days for amitriptyline, 2-3 days for perphenazine. |
| Protein binding | Amitriptyline: 96% bound to albumin and alpha-1-acid glycoprotein; perphenazine: 90-95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Amitriptyline: 10-20 L/kg, indicating extensive tissue distribution; perphenazine: 10-25 L/kg, reflecting high lipophilicity and tissue uptake. |
| Bioavailability | Amitriptyline: 45-60% due to first-pass metabolism; perphenazine: 40-60% due to first-pass metabolism; both extensively metabolized by CYP2D6 and CYP3A4. |
| Onset of Action | Oral: antidepressant effect 2-4 weeks; antipsychotic effect 2-7 days; sedative effect 30-60 minutes. |
| Duration of Action | Amitriptyline: 4-8 hours for sedative effects; antidepressant effect persists for days after discontinuation due to active metabolite nortriptyline (half-life 18-44 hours). Perphenazine: 6-12 hours for antipsychotic effect. |
1 tablet (perphenazine 4 mg / amitriptyline 10 mg) orally 3 times daily, maximum 8 tablets daily.
| Dosage form | TABLET |
| Renal impairment | GFR 10-50 mL/min: reduce dose by 50%. GFR <10 mL/min: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated. |
| Pediatric use | Not recommended for children <12 years; for adolescents 12-18 years: perphenazine 0.1-0.5 mg/kg/day divided q6-8h, amitriptyline 1-3 mg/kg/day divided q6-8h, maximum perphenazine 16 mg/day, amitriptyline 150 mg/day. |
| Geriatric use | Initial dose: one-half tablet (2 mg/5 mg) orally 2-3 times daily; titrate slowly, maximum perphenazine 24 mg/day, amitriptyline 100 mg/day. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRIAVIL 4-10 (TRIAVIL 4-10).
| Breastfeeding | Amitriptyline and perphenazine are excreted into breast milk. M/P ratio for amitriptyline (approx. 1.0-1.5) and perphenazine (unknown). Monitor infant for sedation, respiratory depression, and extrapyramidal symptoms. Avoid breastfeeding or use alternative therapy due to potential adverse effects. |
| Teratogenic Risk | First trimester: Increased risk of congenital malformations (cardiovascular, neural tube defects) associated with amitriptyline (FDA category D). Perphenazine (FDA category C) may cause extrapyramidal effects. Second and third trimesters: Risk of neonatal withdrawal (tachycardia, irritability, respiratory distress) and anticholinergic effects. Avoid use, especially after 36 weeks, due to risk of neonatal sedation and withdrawal. |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders (per amitriptyline). Not approved for pediatric use. Increased mortality in elderly patients with dementia-related psychosis (per perphenazine).
| Serious Effects |
Concurrent use with MAOIs, within 14 days of MAOI use, recent myocardial infarction, QT prolongation, severe hepatic impairment, narrow-angle glaucoma, urinary retention, hypersensitivity to components.
| Precautions | Suicidality, neuroleptic malignant syndrome, tardive dyskinesia, seizures, anticholinergic effects, cardiotoxicity (QT prolongation), mania/hypomania, sedation, orthostatic hypotension, agranulocytosis, hyperprolactinemia, withdrawal symptoms. |
Loading safety data…
| Fetal Monitoring | Monitor fetal growth and development with serial ultrasound. Assess for neonatal withdrawal symptoms (e.g., irritability, feeding difficulties, respiratory distress) after delivery. Monitor maternal blood pressure, heart rate, and ECG. Assess for extrapyramidal symptoms and anticholinergic effects. |
| Fertility Effects | Amitriptyline may cause menstrual irregularities and decreased libido; perphenazine may cause galactorrhea, amenorrhea, and reduced fertility due to prolactin elevation. Both may impair fertility. Effects are reversible upon discontinuation. |